DE69529708T2 - Herstellung von stabilen Zink-Insulinanalogen-Kristallen - Google Patents

Herstellung von stabilen Zink-Insulinanalogen-Kristallen

Info

Publication number
DE69529708T2
DE69529708T2 DE69529708T DE69529708T DE69529708T2 DE 69529708 T2 DE69529708 T2 DE 69529708T2 DE 69529708 T DE69529708 T DE 69529708T DE 69529708 T DE69529708 T DE 69529708T DE 69529708 T2 DE69529708 T2 DE 69529708T2
Authority
DE
Germany
Prior art keywords
human insulin
solution
zinc
insulin
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69529708T
Other languages
German (de)
English (en)
Other versions
DE69529708D1 (de
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69529708(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69529708D1 publication Critical patent/DE69529708D1/de
Application granted granted Critical
Publication of DE69529708T2 publication Critical patent/DE69529708T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE69529708T 1994-06-16 1995-06-14 Herstellung von stabilen Zink-Insulinanalogen-Kristallen Expired - Lifetime DE69529708T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (2)

Publication Number Publication Date
DE69529708D1 DE69529708D1 (de) 2003-04-03
DE69529708T2 true DE69529708T2 (de) 2003-10-16

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529708T Expired - Lifetime DE69529708T2 (de) 1994-06-16 1995-06-14 Herstellung von stabilen Zink-Insulinanalogen-Kristallen

Country Status (29)

Country Link
US (1) US5504188A (cg-RX-API-DMAC7.html)
EP (1) EP0692489B1 (cg-RX-API-DMAC7.html)
JP (1) JP3595607B2 (cg-RX-API-DMAC7.html)
KR (1) KR100369951B1 (cg-RX-API-DMAC7.html)
CN (1) CN1184234C (cg-RX-API-DMAC7.html)
AT (1) ATE233278T1 (cg-RX-API-DMAC7.html)
AU (1) AU697794B2 (cg-RX-API-DMAC7.html)
BR (1) BR9502798A (cg-RX-API-DMAC7.html)
CA (1) CA2151563C (cg-RX-API-DMAC7.html)
CO (1) CO4410205A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ286066B6 (cg-RX-API-DMAC7.html)
DE (1) DE69529708T2 (cg-RX-API-DMAC7.html)
DK (1) DK0692489T3 (cg-RX-API-DMAC7.html)
ES (1) ES2188637T3 (cg-RX-API-DMAC7.html)
FI (1) FI952930L (cg-RX-API-DMAC7.html)
HU (1) HUT73495A (cg-RX-API-DMAC7.html)
IL (1) IL114152A (cg-RX-API-DMAC7.html)
IN (1) IN178919B (cg-RX-API-DMAC7.html)
MY (1) MY130551A (cg-RX-API-DMAC7.html)
NO (1) NO952334L (cg-RX-API-DMAC7.html)
NZ (1) NZ272358A (cg-RX-API-DMAC7.html)
PE (1) PE21896A1 (cg-RX-API-DMAC7.html)
PL (1) PL180968B1 (cg-RX-API-DMAC7.html)
RO (1) RO113529B1 (cg-RX-API-DMAC7.html)
RU (1) RU2156257C2 (cg-RX-API-DMAC7.html)
SI (1) SI0692489T1 (cg-RX-API-DMAC7.html)
TW (1) TW379228B (cg-RX-API-DMAC7.html)
YU (1) YU39595A (cg-RX-API-DMAC7.html)
ZA (1) ZA954942B (cg-RX-API-DMAC7.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE69806582T2 (de) * 1997-03-20 2003-02-13 Novo Nordisk A/S, Bagsvaerd Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
ES2202910T3 (es) * 1997-11-12 2004-04-01 Alza Corporation Composiciones de farmacos regulados para la administracion transdermica por electrotranporte.
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
PT1121144E (pt) * 1998-10-16 2002-11-29 Novo Nordisk As Preparados de insulina concentrada estavel para administracao pulmonar
PL347171A1 (en) * 1998-10-16 2002-03-25 Novo Nordisk As Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
DK1772464T3 (da) * 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US7875700B2 (en) 2004-07-19 2011-01-25 Biocon Limited Cation complexes of insulin compound conjugates, formulation and uses thereof
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CA2614116A1 (en) 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
SI1951658T1 (sl) 2005-11-17 2012-11-30 Lilly Co Eli Antagonisti glukagonskega receptorja priprava interapevtska uporaba
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
AU2007244971B2 (en) 2006-04-24 2012-01-19 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PT2079732E (pt) 2006-05-29 2012-02-02 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
KR20100017667A (ko) 2007-06-01 2010-02-16 노보 노르디스크 에이/에스 안정한 비-수성의 약학 조성물
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
MX2010003979A (es) * 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
MX2011005037A (es) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Compuestos de adamantilo benzamida.
MX2011007929A (es) 2009-01-28 2011-08-17 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada.
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
KR20120055653A (ko) * 2009-08-11 2012-05-31 바이오콘 리미티드 크로마토그래피 방법 및 그의 정제된 화합물
JP6110312B2 (ja) 2011-02-01 2017-04-05 ノヴォ ノルディスク アー／エス インスリンの精製
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
EP3077414B1 (en) 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
KR20220161422A (ko) 2020-03-31 2022-12-06 프로토머 테크놀로지스 인크. 비시날 디올에 대한 선택적인 반응을 위한 접합체
CA3198757A1 (en) 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE533298A (cg-RX-API-DMAC7.html) *
BE533252A (cg-RX-API-DMAC7.html) *
BE515508A (cg-RX-API-DMAC7.html) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
WO1990001038A1 (en) * 1988-07-20 1990-02-08 Nordisk Gentofte A/S Human insulin analogs and preparations containing them
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
BR9407508A (pt) * 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
SI0692489T1 (en) 2003-06-30
ATE233278T1 (de) 2003-03-15
IN178919B (cg-RX-API-DMAC7.html) 1997-07-19
NZ272358A (en) 1996-12-20
IL114152A0 (en) 1995-10-31
RO113529B1 (ro) 1998-08-28
RU2156257C2 (ru) 2000-09-20
CZ154195A3 (en) 1996-02-14
FI952930A7 (fi) 1995-12-17
NO952334L (no) 1995-12-18
CA2151563C (en) 2007-08-07
HU9501715D0 (en) 1995-08-28
FI952930L (fi) 1995-12-17
BR9502798A (pt) 1996-06-04
AU2168195A (en) 1996-01-04
CN1184234C (zh) 2005-01-12
ES2188637T3 (es) 2003-07-01
FI952930A0 (fi) 1995-06-14
EP0692489A1 (en) 1996-01-17
HUT73495A (en) 1996-08-28
PE21896A1 (es) 1996-06-15
EP0692489B1 (en) 2003-02-26
US5504188A (en) 1996-04-02
JP3595607B2 (ja) 2004-12-02
PL180968B1 (pl) 2001-05-31
AU697794B2 (en) 1998-10-15
KR960000922A (ko) 1996-01-25
CZ286066B6 (cs) 2000-01-12
KR100369951B1 (ko) 2003-03-28
YU39595A (sh) 1997-08-22
ZA954942B (en) 1996-12-17
JPH08169899A (ja) 1996-07-02
CA2151563A1 (en) 1995-12-17
TW379228B (en) 2000-01-11
RU95110107A (ru) 1997-05-10
MY130551A (en) 2007-06-29
NO952334D0 (no) 1995-06-13
DE69529708D1 (de) 2003-04-03
IL114152A (en) 1999-12-31
CO4410205A1 (es) 1997-01-09
CN1128271A (zh) 1996-08-07
DK0692489T3 (da) 2003-03-31
PL309099A1 (en) 1995-12-27

Similar Documents

Publication Publication Date Title
DE69529708T2 (de) Herstellung von stabilen Zink-Insulinanalogen-Kristallen
DE69816409T2 (de) Kristallines Parathyroidhormon
AT408611B (de) Insulinanalogon-protamin-komplex
DE3788684T2 (de) Peptide.
DE3685668T2 (de) Peptide.
DE3687500T2 (de) Insulinabkoemmlinge und arzneimittel die diese enthalten.
DE69428860T2 (de) Insulin Formulierung
DE69631996T2 (de) Verfahren zur Herstellung von acylierten Proteinpuder
DE69416409T2 (de) Asp-b28-insulinkristalle
DE3880346T2 (de) Insulinderivate.
EP0885961B1 (de) Neue Insulinderivate mit schnellem Wirkungseintritt
DE69632224T2 (de) Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer
DE3650101T2 (de) Analoga von Insulin und deren Herstellungsmethode.
DE60102899T2 (de) Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
DE69500652T2 (de) Nefazodon-Salze mit verbesserter Auflösungsgeschwindigkeit
US5597893A (en) Preparation of stable insulin analog crystals
EP0291863B1 (de) Mischkristalle aus Insulin und Insulinderivaten, Verfahren zur Herstellung dieser Mischkristalle und diese Mischkristalle enthaltende pharmazeutische Mittel
CH650678A5 (de) Pharmazeutisches mittel aus human-insulin und human-proinsulin.
CH650679A5 (de) Gegen diabetes mellitus wirksames pharmazeutisches mittel.
DE4140381A1 (de) Neue synthetische isohirudine mit verbesserter stabilitaet
DE69829953T2 (de) Kristallisation von proteinen
DE1940130A1 (de) Injizierbare Insulinaufbereitungen fuer klinische Zwecke und Verfahren zu ihrer Herstellung
EP0622376B1 (de) Amorphe monosphärische Formen von Insulinderivaten
CH650680A5 (de) Pharmazeutisches mittel aus human-insulin, human-c-peptid und human-proinsulin.
EP1558641B1 (de) Kristalle von insulinanaloga und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KOENIG SZYNKA TILMANN VON RENESSE, 40549 DUESSELDO